This is a working overview of bremelanotide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-21 and is reviewed periodically as new material appears.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Some manufacturers are also trying to improve on the traditional design by altering properties within these machines other than the pressure driving the sample through the orifice. One such example is Constant Systems, who have recently shown that their Cell Disruptors not only match the performance of a traditional French Press, but also that they are striving towards attaining the same results at a much lower power. Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (up to 90,000 psi) to safely, conveniently and reproducibly control the actions of molecules in biological samples, e.g., the rupture (lysis) of cells and tissues from human, animal, plant, and microbial sources, and the inactivation of pathogens. PCT-enhanced systems (instruments and consumables) address some challenging problems inherent in biological sample preparation. PCT advantages include: (a) extraction and recovery of more membrane proteins, (b) enhanced protein digestion, (c) differential lysis in a mixed sample base, (d) pathogen inactivation, (e) increased DNA detection, and (f) exquisite sample preparation process control. The Microfluidizer method used for cell disruption strongly influences the physicochemical properties of the lysed cell suspension, such as particle size, viscosity, protein yield and enzyme activity.
Results showed strong effects within the first and third dimensions for all conditions, especially with DMT, and suggested strong intrastability of elicited reactions independently of the condition for the OB and VR scales. The effects of parenterally administered DMT have been described by Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved). The perceptual effects included feeling strange, closed-eye imagery such as beautiful colored kaleidoscopic images, fast-moving geometric patterns, and complex and wonderful scenes alternating very rapidly, open-eye psychedelic visuals such as moving patterns, patterns becoming heads of animals, and people's faces seeming to be masks, perceptual disturbances and distortions, yellowing of visual field, and rare auditory changes. Other effects included feeling intoxicated or stoned, everything feeling blurry, feeling a rush, time dilation, loss of spatial perception, ego dissolution, feeling as if one has died or no longer exists, feeling like one has no body, feeling that one is moving at the speed of light, feeling like one is gazing upon the entire universe, and encounters with strange entities or creatures. Emotional effects included emotional changes, euphoria, imagery being associated with deep emotional content and connotation, feeling overwhelmed, anxiety and fear, feeling like one can't breathe, a sense of dread and doom, and wanting one's mother.
Pribram of Radford University in Virginia; Dabney Ewin of Tulane Medical Center in New Orleans; surgeon Ángel Escudero, of Spain, who operated without anaesthetic; the 1962 social conformity experiments of Stanley Milgram; stage hypnosis with stage hypnotist Andrew Newton, in Blackpool, who makes participants on stage think that they are one of the Seven Dwarfs. Narrated by Michael Angelis, directed by Graham Moore, produced by David Britland, made by Open Media. In 2022 the film was the subject of a lengthy article 6 November Rave New World, with Charles Grob, Alexander Shulgin. Narrated by Tom Baker, produced by Phil Craig, directed by Paul Sen, made by McDougall Craig Productions 20 November Brave New Babies, about prenatal and perinatal psychology and cognitive musicology of Brent Logan of Oregon who had adapted the work of child psychologist Lee Salk (whose brother Jonas Salk had invented a vaccine for polio) in the 1970s, with psychologist Prof Peter Hepper of Queen's University Belfast; the neuroscientist Marian Diamond and environmental enrichment; pediatrician Prof Michael Lazarev and the Children's Rehabilitation Medicine Centre in Moscow.
=== Studies in vitro === Epitalon appears to induce telomere elongation via increased telomerase activity in human somatic cells in vitro, based on a study in human fibroblast cell cultures. Elongation of telomeres by epitalon was sufficient to surpass the Hayflick limit in a cell culture of human fetal fibroblast cells, extending their proliferative potential from termination at the 34th passage in the control cell population to beyond the 44th passage in the treated cell population, while increasing the lengths of their telomeres to levels comparable to those of cells in the original culture. Epitalon induces decondensation of heterochromatin near the centromeres in cultured lymphocytes originating from samples taken from humans of ages 76 to 80 years. Epitalon appears to inhibit the synthesis of the MMP9 protein in vitro in aging skin fibroblasts.
Sources: en.wikipedia.org
==== UK ==== Classified as a controlled drug, listed under Schedule IV, Part I (CD Benz POM) of the Misuse of Drugs Regulations 2001, allowing possession with a valid prescription. The Misuse of Drugs Act 1971 makes it illegal to possess the drug without a prescription, and for such purposes, it is classified as a Class C drug.
A pre-injection tuberculin skin test is usually carried out before administering the BCG vaccine. A reactive tuberculin skin test is a contraindication to BCG due to the risk of severe local inflammation and scarring; it does not indicate immunity. BCG is also contraindicated in certain people who have IL-12 receptor pathway defects. BCG is given as a single intradermal injection at the insertion of the deltoid. If BCG is accidentally given subcutaneously, then a local abscess may form (a "BCG-oma") that can sometimes ulcerate, and may require treatment with antibiotics immediately, otherwise without treatment it could spread the infection, causing severe damage to vital organs. An abscess is not always associated with incorrect administration, and it is one of the more common complications that can occur with the vaccination. Numerous medical studies on the treatment of these abscesses with antibiotics have been done with varying results, but the consensus is once pus is aspirated and analysed, provided no unusual bacilli are present, the abscess will generally heal on its own in a matter of weeks. The characteristic raised scar that BCG immunization leaves is often used as proof of prior immunization. This scar must be distinguished from that of smallpox vaccination, which it may resemble. When given for bladder cancer, the vaccine is not injected through the skin but is instilled into the bladder (intravesical) through the urethra using a soft catheter.
Meta's Llama models, which have been described as open-source by Meta, were adopted by U.S. defense contractors like Lockheed Martin and Oracle after unauthorized adaptations by Chinese researchers affiliated with the People's Liberation Army (PLA) came to light. The Open Source Initiative and others have contested Meta's use of the term open-source to describe Llama, due to Llama's license containing an acceptable use policy that prohibits use cases including non-U.S. military use. Chinese researchers used an earlier version of Llama to develop tools like ChatBIT, optimized for military intelligence and decision-making, prompting Meta to expand its partnerships with U.S. contractors to ensure the technology could be used strategically for national security. These applications now include logistics, maintenance, and cybersecurity enhancements.
In medicine, oxygen saturation, commonly referred to as "sats", measures the percentage of hemoglobin binding sites in the bloodstream occupied by oxygen. At low partial pressures of oxygen, most hemoglobin is deoxygenated. At around 90% (the value varies according to the clinical context) oxygen saturation increases according to an oxygen-hemoglobin dissociation curve and approaches 100% at partial oxygen pressures of >11 kPa. A pulse oximeter relies on the light absorption characteristics of saturated hemoglobin to give an indication of oxygen saturation.
Proteins of interest are usually part of a complex mixture of multiple proteins and molecules, which co-exist in the biological medium. This presents two significant problems. First, the two ionization techniques used for large molecules only work well when the mixture contains roughly equal amounts of material, while in biological samples, different proteins tend to be present in widely differing amounts. If such a mixture is ionized using electrospray or MALDI, the more abundant species have a tendency to "drown" or suppress signals from less abundant ones. Second, mass spectrum from a complex mixture is very difficult to interpret due to the overwhelming number of mixture components. This is exacerbated by the fact that enzymatic digestion of a protein gives rise to a large number of peptide products. In light of these problems, the methods of one- and two-dimensional gel electrophoresis and high performance liquid chromatography are widely used for separation of proteins. The first method fractionates whole proteins via two-dimensional gel electrophoresis. The first-dimension of 2D gel is isoelectric focusing (IEF). In this dimension, the protein is separated by its isoelectric point (pI) and the second-dimension is SDS-polyacrylamide gel electrophoresis (SDS-PAGE). This dimension separates the protein according to its molecular weight. Once this step is completed in-gel digestion occurs. In some situations, it may be necessary to combine both of these techniques. Gel spots identified on a 2D Gel are usually attributable to one protein.
Sources: en.wikipedia.org
=== Pharmacodynamics === The exact mechanism of action of theacrine is uncertain, as no binding affinities have been published. However, animal research involving selective A1 and A2A adenosine agonists found theacrine pretreatment attenuated the expected motor depression induced by adenosine agonism, indicating that theacrine is likely an adenosine antagonist. Administration of selective dopamine D1 and D2 antagonists demonstrate that, similarly to caffeine, the behavioural effects of theacrine are in part mediated by dopamine receptors.
Cadmium selenide quantum dots emit bright luminescence under UV excitation (He–Cd laser, for example). The color of this luminescence can be green, yellow or red depending on the particle size. Colloidal solutions of those particles are used for imaging of biological tissues and solutions with a fluorescence microscope. In molecular biology, cadmium is used to block voltage-dependent calcium channels from fluxing calcium ions, as well as in hypoxia research to stimulate proteasome-dependent degradation of Hif-1α. Cadmium-selective sensors based on the fluorophore BODIPY have been developed for imaging and sensing of cadmium in cells. One powerful method for monitoring cadmium in aqueous environments involves electrochemistry. By employing a self-assembled monolayer one can obtain a cadmium selective electrode with a ppt-level sensitivity.
Since 1947, the Doomsday Clock of the Bulletin of the Atomic Scientists has visualized how close the world is to a nuclear war. The Doomsday Clock reached a high point in 1953, when the Clock was set to two minutes until midnight after the U.S. and the Soviet Union began testing hydrogen bombs, and in 2018, following the failure of world leaders to address tensions relating to nuclear weapons and climate change issues. Since 2026, the Clock has been set at 85 seconds to midnight, the closest it has ever been.
The Kockums shipyard responsible for the design of the x-stern on Swedish submarines eventually exported it to Australia with the Collins class as well as to Japan with the Sōryū class. With the introduction of the type 212, the German and Italian Navies came to feature it as well. The US Navy with its Columbia class, the British Navy with its Dreadnought class, and the French Navy with its Barracuda class are all about to join the x-stern family. Hence, as judged by the situation in the early 2020s, the x-stern is about to become the dominant technology. When a submarine performs an emergency surfacing, all depth and trim control methods are used simultaneously, together with propelling the boat upwards. Such surfacing is very quick, so the vessel may even partially jump out of the water, potentially damaging submarine systems.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.